Amgen And AbbVie In Legal Settlement
socalTECH
SEPTEMBER 28, 2017
According to the two, AbbVie will grant a patent license for use and sale of the compound worldwide, on a country-by-country basis. As a result of the settlement, Amgen said it expects to launch its product in Europe in October of 2018, and its product for the United States in 2023.
100 
Let's personalize your content